Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies

International Journal of Geriatric Psychiatry

Volumn 30, Issue 1, 2015, Pages 46-54

  Wesnes, Keith A ^a,b,c   Aarsland, Dag ^d   Ballard, Clive ^e   Londos, Elisabet ^f  

^a Wesnes Cognition Ltd   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Attention; Automated cognitive tests; CDR System; Dementia with Lewy bodies; Episodic memory; Memantine; Parkinson's disease dementia

Indexed keywords

ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; LEVODOPA; MEMANTINE; NEUROLEPTIC AGENT; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; ATTENTION; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; EPISODIC MEMORY; EVENING DOSAGE; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; TREATMENT DURATION; WORD RECOGNITION; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COGNITION; DRUG EFFECTS; LEWY BODY DISEASE; MEMORY; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; REACTION TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; ATTENTION; COGNITION; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MEMANTINE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; REACTION TIME;

EID: 84918769295     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4109     Document Type: Article

References (36)

1. Aarsland D, Ballard C, Walker Z, et al. 2009. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8: 613-618.
2. Andersson M, Wiig EH, Minthon L, Londos E,. 2007. A quick test for cognitive speed: a measure of cognitive speed in dementia with Lewy bodies. Am J Alzheimers Dis Other Dem 22: 313-318.
3. Auning E, Rongve A, Aarsland D,. 2012. Parkinson's disease dementia and dementia with Lewy bodies-epidemiology, risk factors and biomarkers. Norsk Epidemiologi 22: 233-242.
4. Ayre GA, 1998. The comparative neuropsychology of dementia. Unpublished PhD Thesis. Newcastle University.
5. Ballard CG, Aarsland D, McKeith IG, et al. 2002. Fluctuations in attention: PD de mentia vs. DLB with Parkinsonism. Neurology 59: 1714-1720.
6. Ballard CG, Walker M, O'Brien JT, Rowan EN, McKeith IG,. 2001. The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 16: 494-498.
7. Bronnick K, Ehrt U, Emre M, et al. 2006. Attentional deficits affect activities of daily living in dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 77: 1136-1142.
8. Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB,. 1989. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 52: 709-717.
9. Calderon J, Perry RJ, Erzinclioglu SW, et al. 2001. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 70: 157-164.
10. Cohen J,. 1988 Statistical Power Analysis for the Behavioral Sciences (2nd edn): Lawrence Erlbaum Associates: Hillsdale, NJ.
11. Donders FC,. 1868. On the speed of mental processes. In Attention and Performance II. Acta Psychologica, Koster WG, (ed.). 30: 412-431.
12. Emre M, Aarsland D, Albanese A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518.
13. Emre M, Aarsland D, Brown R, et al. 2007. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22: 1689-1707.
14. Emre M, Tsolaki M, Bonuccelli U, et al. 2010. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 969-977.
15. Gelinas I, Gauthier L, McIntyre M, Gauthier S,. 1999. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 53: 471-481.
16. Logsdon RG, Gibbons LE, McCurry SM, Teri L,. 1999. Quality of life in Alzheimer's disease: patient and caregiver reports. J Ment Health Aging 5: 21-32.
17. Lippa CF, Duda JE, Grossman M, et al. 2007. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812-19.
18. Matsunaga S, Kishi T, Iwata N,. (2013). Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry. doi: 10.1016/j.jagp.2013.11.007
19. McKeith IG, Del Ser T, Spano P, et al. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
20. McKeith IG, Dickson DW, Lowe J,. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65: 1863-1872.
21. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK,. 1992. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 22: 911-922.
22. McShane R, Areosa Sastre A, Minakaran N,. 2006. Memantine for dementia. Cochrane Database Syst Rev 2: CD003154.
23. Nacher J, Alonso-Llosa G, Rosell DR, McEwen BS,. 2003. NMDA receptor antagonist treatment increases the production of new neurons in the aged rat hippocampus. Neurobiol Aging 24: 273-284.
24. Nicholl CG, Lynch S, Kelly CA, et al. 1995. The cognitive drug research computerised assessment system in the evaluation of early dementia-is speed of the essence? Int J Geriatr Psychiatry 10: 199-206.
25. Rockwood K,. 2004. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 677-685.
26. Rowan E, McKeith IG, Saxby BK, et al. 2007. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 23: 161-167.
27. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK,. 1991. The cognitive drug research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 6: 95-102.
28. Simpson PM, Wesnes KA, Christmas L,. 1989. A computerised system for the assessment of drug induced performance changes in young elderly or demented populations. Br J Clin Pharmacol 27: 711P-712P.
29. Vellas B, Cunha L, Gertz HJ, et al. 2005. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin1 21: 1423-1429.
30. Walker MP, Ayre GA, Ashton CH, et al. 1999. A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias. Hum Psychopharmacol 14: 483-489.
31. Walker MP, Ayre GA, Cummings JL, et al. 2000a. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology 54: 1616-1624.
32. Walker MP, Ayre GA, Perry EK, et al. 2000b. Quantification and characterisation of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 11: 327-335.
33. Wesnes KA, McKeith IG, Edgar C, et al. 2005. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65: 1654-1656.
34. Wesnes KA, McKeith IG, Ferrara R, et al. 2002. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13: 183-192.
35. Wesnes KA, Pincock C,. 2002. Practice effects on cognitive tasks: a major problem? Lancet Neurol 1: 473.
36. Wesnes KA, Edgar C, Wroe SJ, Dean ADP,. 2009. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy Epilepsy & Behavior 14: 522-528.